Sterjev, Zoran
Preferred name
Sterjev, Zoran
Official Name
Sterjev, Zoran
Main Affiliation
Email
zost@ff.ukim.edu.mk
17 results
Now showing 1 - 10 of 17
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, Development and validation of a bioanalytical LC-UV method with solid-phase extraction for determination of valproic acid in saliva.(Macedonian Academy of Sciences and Arts/Walter de Gruyter GmbH, 2012-06); ; ; A bioanalytical HPLC method with UV detection for the determination of the antiepileptic drug valproic acid in human saliva has been developed and validated. Saliva represents an alternative matrix for therapeutic monitoring of antiepileptic drugs due to the increasing interest in free drug concentration. The proposed method involved solid-phase extraction for sample preparation and yielded very good mean recoveries of 99.4 % and 97.9 % for valproic acid and IS, respectively. The calibration function for valproic acid was linear over the concentration range of 1.0-50.0 μg mL⁻¹ (R² = 0.9989). Within-run and between-run precision and accuracy were studied at four concentrations and RSDs were less than 7.3 and 2.2 %, while accuracy values were higher than 96.8 and 97.5 %, respectively. The described method provides sensitivity, linearity, precision, accuracy and is suitable for analyses of valproic acid in saliva samples. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Development and validation of a bioanalytical LC-UV method with solid-phase extraction for determination of valproic acid in saliva(Walter de Gruyter GmbH, 2012-06-28); - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Community pharmacy practice in Montenegro in the period January-April 2020(Macedonian pharmaceutical association, 2022); ; - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Nutritional information and labels in relation to food advertising: a survey of Macedonian consumers(Macedonian Pharmaceutical Association, 2024); ; - Some of the metrics are blocked by yourconsent settings
Item type:Publication, AKR1D1*36 C>T (rs1872930) allelic variant is associated with variability of the CYP2C9 genotype predicted pharmacokinetics of ibuprofen enantiomers - a pilot study in healthy volunteers(Walter de Gruyter GmbH, 2019-09-01); ; ; ; Geskovska, Nadica MatevskaThe relative contribution of CYP2C9 allelic variants to the pharmacokinetics (PK) of ibuprofen (IBP) enantiomers has been studied extensively, but the potential clinical benefit of pharmacogenetically guided IBP treatment is not evident yet. The role of AKR1D1*36C>T (rs 1872930) allelic variant in interindividual variability of CYP450 mediated drug metabolism was recently elucidated. A total of 27 healthy male subjects, volunteers in IBP single-dose two-way cross-over bioequivalence studies were genotyped for CYP2C9*2, CYP2C9*3 and AKR1D1*36 polymorphisms. The correlation between CYP2C9 and AKR1D1 genetic profile and the PK parameters for S-(+) and R-(-)-IBP was evaluated. Remarkable changes in the PK values pointing to reduced CYP2C9 enzyme activity were detected only in the CYP2C9*2 allelic variant carriers. Statistically significant association between the AKR1D1*36 allele and the increased IBP metabolism (low AUC0-t and 0-∞, high Cltot and short tmax values for both enantiomers) was observed in subjects carrying the CYP2C9 *1/*3 or CYP2C9*1/*1 genotype. The clinical value of concomitant CYP2C9 and AKR1D1 genotyping has to be further verified. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Role and activities of pharmacists in RN Macedonia at the beginning of COVID-19 pandemic: March-April 2020(Macedonian pharmaceutical association, 2022); ; ; ; - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Hospital pharmacists as key factor for improvement of adverse drug reactions reporting practice, the Macedonian case(2019-05); - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Community pharmacists in RN Macedonia at the frontline of COVID-19 pandemic beginning: March-April 2020(Macedonian pharmaceutical association, 2022); ; ; ; - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Evaluation of Correlation Between the Pharmacogenetic Profiles of Risperidone Treated Psychiatry Patients with Plasma and Urine Concentration of Risperidone and its Active Moiety 9-OH Risperidone Determined with Optimized Bioanalytical LC Method(Walter de Gruyter GmbH, 2018-12-01); ; Atypical antipsychotic risperidone is widely used first-line monotherapy in schizophrenia and combined therapy in bipolar disorders. Therapeutic plasma concentrations of risperidone and its active moiety are directly influenced by genetic variations in metabolic CYP450 enzymes (CYP2D6 and CYP3A4/5) and transporter (ABCB1) protein and additional environmental factors. Since active metabolite 9-OH risperidone has a greater percentage of the pharmacologically active fraction and is equipotent to the parent drug risperidone, it is assumed that it contributes significantly to therapeutic and adverse effects. Unpredictable dose/concentration ratio, narrow therapeutic index, number of interactions, along with serious adverse reactions (ADR), raises the need for individualization of risperidone treatment and establishing of good therapeutic regime using TDM. A simple and reliable validated bioanalytical liquide-liquide extraction HPLC/UV method was applied for the simultaneous determination of risperidone and its active metabolite, 9-OH risperidone, in human plasma and urine of 52 hospitalized schizophrenia/bipolar disorder patients treated with risperidone as monotherapy and in polytherapy. All the patients were previously genotyped for CYP2D6 (EM=30, EM/IM=14, IM=4 IM/PM=1 and PM=3) and ABCB1 using Real-Time PCR methods with TaqMan SNP genotyping suitable assays according to the guidelines of the manufacturer (Life Technologies, USA).The influence of CYP2D6 phenotype on metabolic ratio MR (Ris/9-OHRis) in plasma (p=0.012) and in urine (p=0.048) was confirmed. Statistically significant correlation (R2=55.53%, Rho=0.844, p<0,0001) for MR in both plasma and urine indicates that urine may be utilized as appropriate media for initial CYP2D6 phenotype identification and selection of patients on risperidone treatment with high risk for ADR. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Synthesis, Biological Evaluation, and Molecular Docking Studies of Novel Coumarin–Triazole–Isatin Hybrids as Selective Butyrylcholinesterase Inhibitors(MDPI AG, 2025-05-11); ; Mihajloska, Evgenija<jats:p>A series of 21 novel coumarin–triazole–isatin hybrids was synthesized and evaluated for their potential as multitarget agents in Alzheimer’s disease (AD). The compounds featured variations in alkyl linker length that connects coumarin and triazole and substitution at the 5-position of the isatin ring. Several derivatives showed potent butyrylcholinesterase (BChE) inhibition with selectivity over acetylcholinesterase (AChE). The lead compound, 6c1, exhibited strong BChE inhibition (IC50 = 1.74 μM), surpassing donepezil. Enzyme kinetics revealed a mixed-type mechanism, while molecular docking studies confirmed dual binding at catalytic and peripheral sites. Structure–activity relationship (SAR) analysis highlighted the influence of linker flexibility and steric/electronic effects of substituents. The observed BChE selectivity, combined with favorable in vitro profiles, identifies these hybrids as promising leads for AD drug development.</jats:p>